Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1928206 | 0.92 | DPP4 (0.41) | DPP4CYP3A4 | |
| SCHEMBL12531800 | 0.84 | DPP4 (0.65) | DPP4CYP3A4 | |
| SCHEMBL1928957 | 0.83 | DPP4 (0.51) | DPP4CYP3A4 | |
| SCHEMBL1928385 | 0.82 | HPGD (0.41) | DPP4CYP3A4 | |
| SCHEMBL1927171 | 0.81 | DPP4 (0.49) | DPP4CYP3A4 | |
| SCHEMBL1927895 | 0.75 | DPP4 (0.50) | DPP4CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1928691 | 0.75 | DPP4 (0.42) | DPP4CYP3A4 | |
| SCHEMBL1927164 | 0.71 | DPP4 (0.42) | DPP4CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL3840942 | 0.69 | DPP4 (0.44) | DPP4CYP3A4 | |
| SCHEMBL1929429 | 0.68 | DPP4 (0.38) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956061-B2 | Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-06-07 | — | — | US | disclosed |
| EP-1841770-B1 | BICYCLIC PYRIMIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090105210-A1 | Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105210-A1 | Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.